Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 70.98% is in line with its 5-year average of 78.36%, near the high end of its 5-year range (-63.17%–95.71%).
109.77% above its 12-month average of 33.84%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 8.14%.
GROSS MARGIN
70.98%
GROSS MARGIN AVG TTM
33.84%
GROSS MARGIN AVG 3Y
73.54%
GROSS MARGIN AVG 5Y
78.36%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+109.77%
CURRENT VS 3Y AVG
-3.48%
CURRENT VS 5Y AVG
-9.42%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
58.99%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
+20.32%
vs the sector median at left
Market Cap
$24.68B
Gross Margin
92.62%
TTM Avg
92.70%
3Y Avg
93.10%
5Y Avg
93.74%
Market Cap
$25.68B
Gross Margin
36.77%
TTM Avg
35.27%
3Y Avg
37.10%
5Y Avg
37.60%
Market Cap
$26.57B
Gross Margin
27.85%
TTM Avg
27.30%
3Y Avg
28.39%
5Y Avg
31.16%
Market Cap
$26.88B
Gross Margin
59.30%
TTM Avg
57.84%
3Y Avg
57.54%
5Y Avg
57.23%
Market Cap
$27.29B
Gross Margin
33.15%
TTM Avg
32.39%
3Y Avg
33.17%
5Y Avg
35.04%
Market Cap
$21.24B
Gross Margin
86.14%
TTM Avg
88.58%
3Y Avg
89.63%
5Y Avg
90.66%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioNTech SE (BNTX) | $24.29B | 70.98% | 33.84% | 73.54% | 78.36% |
| Incyte Corporation (INCY)vs › | $24.68B | 92.62% | 92.70% | 93.10% | 93.74% |
| West Pharmaceutical Services, Inc. (WST)vs › | $25.68B | 36.77% | 35.27% | 37.10% | 37.60% |
| Labcorp Holdings Inc. (LH)vs › | $26.57B | 27.85% | 27.30% | 28.39% | 31.16% |
| Mettler-Toledo International Inc. (MTD)vs › | $26.88B | 59.30% | 57.84% | 57.54% | 57.23% |
| Medline Inc. (MDLN)vs › | $27.15B | 25.02% | 25.55% | 23.71% | 23.71% |
| Quest Diagnostics Incorporated (DGX)vs › | $27.29B | 33.15% | 32.39% | 33.17% | 35.04% |
| United Therapeutics Corporation (UTHR)vs › | $21.24B | 86.14% | 88.58% | 89.63% | 90.66% |
| STERIS plc (STE)vs › | $20.49B | 44.43% | 44.13% | 43.77% | 43.82% |
| GE HealthCare Technologies Inc. (GEHC)vs › | $28.94B | 42.90% | 40.85% | 40.34% | 40.27% |
Gross Margin
71.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 8.14% |
| 2026-03-31 | -63.17% |
| 2025-12-31 | 63.27% |
| 2025-09-30 | 90.24% |
| 2025-06-30 | 70.71% |
| 2025-03-31 | 54.16% |
| 2024-12-31 | 79.54% |
| 2024-09-30 | 85.63% |
| 2024-06-30 | 53.54% |
| 2024-03-31 | 68.50% |
| 2023-12-31 | 87.89% |
| 2023-09-30 | 81.93% |
| 2023-06-30 | 2.86% |
| 2023-03-31 | 92.48% |
| 2022-12-31 | 95.71% |
| 2022-09-30 | 78.25% |
| 2022-06-30 | 76.08% |
| 2022-03-31 | 79.70% |
| 2021-12-31 | 89.46% |
| 2021-09-30 | 80.10% |
| 2021-06-30 | 83.35% |
| 2021-03-31 | 88.62% |
| 2020-12-31 | 88.13% |
| 2020-09-30 | 89.93% |
| 2020-06-30 | 86.57% |
| 2020-03-31 | 78.70% |
| 2019-12-31 | 84.15% |
| 2019-09-30 | 85.24% |
| 2019-06-30 | 78.71% |
| 2019-03-31 | 87.75% |
| 2018-12-31 | 92.98% |
| 2018-09-30 | 86.38% |
| 2018-06-30 | 85.17% |
| 2018-03-31 | 85.17% |
